These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9491902)

  • 1. Plasmapheresis in severe forms of myasthenia gravis.
    Morosetti M; Meloni C; Iani C; Caramia M; Galderisi C; Palombo G; Gallucci MT; Bernardi G; Casciani CU
    Artif Organs; 1998 Feb; 22(2):129-34. PubMed ID: 9491902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of severe forms of myasthenia gravis.
    Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G
    Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of myasthenia gravis with plasmapheresis (author's transl)].
    Reuther P; Wiebecke D; Hertel G; Böske A; Mertens HG
    Dtsch Med Wochenschr; 1979 Dec; 104(51):1806-10. PubMed ID: 520174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Favorable results of plasmapheresis in severe myasthenia gravis].
    Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ
    Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of steroid-induced exacerbation in myasthenia gravis.
    Bae JS; Go SM; Kim BJ
    J Clin Neurosci; 2006 Dec; 13(10):1006-10. PubMed ID: 17074487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis.
    Hilkevich O; Drory VE; Chapman J; Korczyn AD
    Clin Neuropharmacol; 2001; 24(3):173-6. PubMed ID: 11391130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients.
    Carandina-Maffeis R; Nucci A; Marques JF; Roveri EG; Pfeilsticker BH; Garibaldi SG; de Deus-Silva L
    Arq Neuropsiquiatr; 2004 Jun; 62(2B):391-5. PubMed ID: 15273832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prednisone followed by thymectomy in myasthenia gravis.
    Mann JD; Johns TR; Campa JF; Muller WH
    Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of plasmapheresis before thymectomy in the management of myasthenia gravis].
    Iváñez V; Díez-Tejedor E; Lara M; Barreiro P
    Neurologia; 1994; 9(7):277-81. PubMed ID: 7946422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis.
    Eppel M; Streib EW
    Nebr Med J; 1982 Apr; 67(4):72-4. PubMed ID: 7088214
    [No Abstract]   [Full Text] [Related]  

  • 13. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
    Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
    Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of antenatal myasthenia gravis.
    Carr SR; Gilchrist JM; Abuelo DN; Clark D
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):485-9. PubMed ID: 1870801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
    Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
    Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis: treatment with plasma exchange experiences over 10 years.
    Fornádi L; Horváth R; Szobor A
    Acta Med Hung; 1991; 48(3-4):137-44. PubMed ID: 1822852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.